USV Launces OnArni for management of heart failure

USV Pvt. Ltd. has launched OnArni, a combination of Sacubitril and Valsartan, for treating heart failure, available at an affordable price of Rs. $8 is the cost for each tablet of 50mg. This affordable solution helps tackle the increasing instances of heart failure in India, providing vital care to millions of patients in critical need.

In India, there is a worrying rise in heart failure incidents, with individuals experiencing the condition almost a decade earlier than in other regions globally. This early start creates significant stress for both households and the medical system. Treating heart failure usually involves taking medication for life and leads to frequent hospital stays, resulting in a significant rise in healthcare expenses.

Many people do not follow their prescriptions properly because of the expensive treatment costs, which then negatively impacts their health results. The arrival of bioequivalent OnArni by USV Pvt. Ltd. provides a cost-effective, timely option that assists in easing the financial strain of long-term heart failure therapy.

Prashant Tewari, managing director, USV, stresses the need for affordable heart failure solutions, stating, "As leaders in cardiovascular care, introducing bioequivalent OnArni was a pivotal step for us at USV to ensure heart failure treatment is both affordable and accessible. With a price of Rs. 8 per tablet of the starting dose, OnArni helps patients stay consistent with their medication, which is critical in managing the condition effectively. By alleviating the financial strain that often leads patients to skip doses, we aim to reduce hospital readmissions and improve long-term health outcomes."